Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

seconD-line Folfiri/aflIbercept in proSpecTIvely Stratified, Anti-EGFR resistaNt, Metastatic coloreCTal Cancer patIents With RAS Validated Wild typE Status

NCT04252456 is registered in ClinicalTrials.gov with Gruppo Italiano per lo studio dei Carcinomi dell'Apparato Digerente as lead sponsor.

NCT NCT04252456
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04252456 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
seconD-line Folfiri/aflIbercept in proSpecTIvely Stratified, Anti-EGFR resistaNt, Metastatic coloreCTal Cancer patIents With RAS Validated Wild typE Status
Lead sponsor
Gruppo Italiano per lo studio dei Carcinomi dell'Apparato Digerente
Phase
Not applicable
Overall status
Unknown status
Start date
April 23, 2018
Completion date
February 28, 2021
Enrollment
150 (estimated)
Sites
16

Conditions

As the registry lists them; a condition with its own page is linked.

advanced colorectal cancer